Recombinant Human SPARC Protein (C-6His)

Name: Recombinant Human SPARC Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-0440NP
Availability: InStock

BL-0440NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Other recombinant proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Secreted Protein Acidic and Rich in Cysteine is produced by our Mammalian expression system and the target gene encoding Ala18-Ile303 is expressed with a 6His tag at the C-terminus.
Accession	P09486
Synonym	SPARC; Basement-Membrane Protein 40; BM-40; Osteonectin; ON; Secreted Protein Acidic and Rich in Cysteine; SPARC; ON
Gene Background	Secreted Protein Acidic and Rich in Cysteine (SPARC) is a secreted, evolutionarily conserved collagen-binding glycoprotein and belongs to the SPARC family. SPARC has 286 amino acids and contains an EF-hand in C-termina domain, a follistatin-like domain with Kazal-like sequences. There are two calcium binding sites, one binds 5 - 8 Ca2+ with a low affinity and other on an EF-hand loop that binds a Ca2+ ion with a high affinity. It is highly expressed in tissues undergoing morphogenesis, remodeling and wound repair. SPARC regulate cell growth through interactions with the extracellular matrix (ECM) and cytokines. SPARC bind to numerous proteins of the ECM, affect ECM protein expression, influence cellular adhesion and migration, and modulate growth factor-induced cell proliferation and angiogenesis. SPARC also binds several types of collagen, albumin, thrombospondin, PDGF and cell membranes.
Molecular Mass	33.73 KDa
Apmol Mass	36 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Appears to regulate cell growth through interactions with the extracellular matrix and cytokines. Binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. There are two calcium binding sites; an acidic domain that binds 5 to 8 Ca(2+) with a low affinity and an EF-hand loop that binds a Ca(2+) ion with a high affinity.
Subcellular Location	Secreted, extracellular space, extracellular matrix, basement membrane. Note=In or around the basement membrane.
Protein Families	SPARC family
Database References	HGNC: 11219 OMIM: 182120 KEGG: hsa:6678 STRING: 9606.ENSP00000231061 UniGene: Hs.111779
Associated Diseases	Osteogenesis imperfecta 17 (OI17)

Gene Functions References

Hepatic SPARC expression is associated with liver injury and fibrogenic processes in non-alcoholic fatty liver disease. PMID: 29335425
Plasma samples from lung cancer patients and healthy heavy-smokers controls were tested for levels of COL11A1 and COL10A1 (n = 57 each) and SPARC (n = 90 each). Higher plasma levels of COL10A1 were detected in patients (p PMID: 30227835
The authors have confirmed the presence of SPARC expression in melanoma, Kaposi sarcomas (KS), leiomyosarcomas (LMS) and angiosarcomas (AS) and also detected it for the first time in atypical fibroxanthomas (AFX). PMID: 29660567
Results revealed that hypermethylation of the SPARC promoter was the primary mechanism of SPARC downregulation in prostate cancer. SPARC expression was frequently lost during the promoter hypermethylation but could be restored by 5-Aza-Cdr. PMID: 29207175
Stromal SPARC expression was a useful biomarker for predicting prognosis in patients with resected pancreatic ductal adenocarcinoma. PMID: 29295776
SPARC is closely related to the development of breast cancer and can be used as a tumor marker for breast cancer recurrence. PMID: 29237913
SPARC expression was inversely associated with the degree of malignancy and it had a negative correlation with VEGF-C and VEGF-D expression. Results suggest SPARC might function as a tumor suppressor inhibiting angiogenesis and lymphangiogenesis in ovarian cancer by reducing the expression of VEGF-C and VEGF-D. PMID: 29075785
SPARC may be involved in gastric cancer metastasis by effecting on tumor microenvironment PMID: 29077165
SPARC treatment enhances the epithelial mesenchymal transition signaling pathway via activation of AKT, and exogenous SPARC and tumor expressing SPARC might be associated with tumor progression in head and neck cancers. PMID: 28718842
The epicardial adipose tissue expresses the mRNA of osteopontin, osteoprotegerin, and osteonectin genes that have been implicated in the calcification process; such expression is statistically associated with some components of HDL subclasses in coronary artery disease patients. PMID: 28821297
detection of SPARC mRNA and protein expression levels may facilitate early diagnosis and prognosis assessment of esophageal squamous cell carcinoma. PMID: 28713937
SPARC rs17718347 and rs2347128 single nucleotide polymorphisms are associated with progression-free survival in locally advanced and metastatic pancreatic cancer patients. PMID: 28687963
results demonstrated that loss of miR-211 expression and thus uncontrolled SPARC overexpression might drive progression of hepatocellular carcinoma (HCC), which may provide a novel therapeutic strategy for the treatment of HCC. PMID: 27230656
Data suggest that plasma SPARC levels may be biomarker for vascular complications among Chinese type 2 diabetic patients; patients in lowest SPARC tertile have increased odds of aortic stiffness but reduced odds of peripheral arterial disease. PMID: 28479157
The profiled circulating tumour cells also expressed elevated levels of stem cell markers, and the extracellular matrix protein, SPARC. The expression of SPARC might correspond to an epithelial-mesenchymal transition in pancreatic circulating tumour cells PMID: 28569190
Data suggest that both osteonectin and FGF21 levels in serum are associated with early nephropathy in type 2 diabetes, albeit with different patterns; persistent hyperglycemia may inhibit bone formation leading to osteoporosis. (FGF21 = fibroblast growth factor 21) PMID: 27916484
These results suggest that increased SPARC expression may be an indicator of greater aggressiveness, and may serve as a prognostic factor for triple-negative breast cancer. PMID: 27421134
High expression of SPARC is related to worse prognosis in rectal cancer patients. PMID: 28009327
Tumors with stroma-derived SPARC displayed suppressed growth, inhibited angiogenesis and increased lipid accumulation. Based on the described chaperone function of SPARC, authors hypothesized that SPARC binds albumin complexed with fatty acids and transports them to tumors. PMID: 27776337
Weekly NAB-paclitaxel might be effective for heavily pretreated non-small-cell lung cancer patients. SPARC expression in tumor stroma cells might be a potential negative predictor of NAB-paclitaxel. PMID: 28304139
SPARC-associated signaling pathways are associated with lymphangiogenesis and lymph node metastases of hypopharyngeal cancer. PMID: 29374693
Stromal SPARC expression correlated with the prognosis of patients with resectable biliary carcinoma, and its significance was enhanced in patients treated with adjuvant gemcitabine-based chemotherapy. PMID: 28342122
Studies revealed that SPARC plays a critical role in regulating bone remodeling and maintaining bone mass and quality. The mechanisms by which SPARC influences bone formation, maintenance, and repair might occur through multiple pathways that include the regulation of procollagen processing and assembly in the bone matrix, crosslinking, mineralization, and/or osteoblast/osteoclast differentiation and activity. [review] PMID: 26851678
This study indicates that germline PTCH1 heterozygous mutations play a major role in bone metabolism in patients with NBCCS, in particular in those with PTCH1 protein truncation mutations. SPARC may represent an important downstream modulator of PTCH1 mediation of bone metabolism. PMID: 26890308
The SPARC drives pathological responses in non-small cell lung cancer and idiopathic pulmonary fibrosis by promoting microvascular remodelling and excessive deposition of ECM proteins. PMID: 27759879
proCOL11A1, fibroblast-activated protein, secreted protein acidic and rich in cysteine, and periostin expression was significantly increased in the intratumoral stroma of pancreatic ductal adenocarcinomas compared to paired non-neoplastic pancreata PMID: 29025374
The mRNA and protein levels of SPARC were 5.78-fold higher in cancer tissues compared with the case-matched normal epithelium. High expression levels of SPARC in esophageal squamous cell carcinoma parenchyma were related to lymph node metastasis and poor prognosis (p = 0.049 and p = 0.04). PMID: 28818666
SPARC can serve a dual function role as both predictor for prognosis and potentially biomarker for lymph node metastasis in resected pancreatic cancer patients. PMID: 28119265
SPARC appears to be an important modulator of the actin cytoskeleton, implicating maintenance of muscular function PMID: 27908613
that SPARC-mediated degradation of the extracellular matrix, and its possible association with MMPs, might contribute to progression of phyllodes tumors PMID: 27909812
WIN-dependent increase in the level of SPARC plays a critical role in sensitizing osteosarcoma cells to TRAIL action PMID: 26698404
high SPARC-expression was a significant predictor of poor OS in HPV-negative OPSCC patients using Kaplan-Meier analysis and the log-rank test PMID: 26523779
We identified five new biomarkers: GDF15, osteonectin, TRAP5, TWEAK, and YKL40 as being promising markers for monitoring bone metastases. PMID: 27069189
SPARC levels were not associated with efficacy in patients with MPC. This exploratory analysis does not support making treatment decisions regarding nab-paclitaxel plus gemcitabine or gemcitabine alone in MPC based on SPARC expression. PMID: 26169969
CD90 is upregulated in gastric cancer and inhibits gastric cancer cell apoptosis by modulating the expression level of SPARC protein. PMID: 26329007
SPARC might be an unfavorable indicator in patients with pancreatic cancer, especially in the stroma.[Review] PMID: 26731428
tracheal aspirate SPARC levels predicted development of bronchopulmonary dysplasia or death. PMID: 26656750
SPARC is associated with carcinogenesis of oral squamous epithelium. PMID: 25311631
Studies indicate that SPARC (secreted protein acidic and rich in cysteine) gene is involved in the development and progression of pancreatic ductal adenocarcinoma (PDAC). PMID: 26335014
MLKL upregulation in SPARC overexpressed cells treated with Ara-C, indicates necrosis as a possible cell death process for the SKM-1 cells under these stringent conditions. PMID: 26165695
up-regulation of SPARC by oxLDL is independent of Runx2, and it may be mediated by other transcription factors PMID: 26025968
Tumor-produced SPARC and VCAM1 are regulators of cancer extravasation. PMID: 25925867
miR-29a and miR-29b enhance cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression. PMID: 25786138
SNP1599 differentially regulates osteonectin expression and contributes to variability in bone mass, by a mechanism that may involve differential targeting by miR-433 PMID: 25262637
Reduced expression of SPARC in colorectal cancer tissue is associated with poor prognosis and aggressive clinicopathological features. PMID: 26044224
Three functional SPARC SNPs are associated with an increased risk of coal workers' pneumoconiosis in a Chinese population. PMID: 25126876
reduced expression in the bone marrow biopsy specimen in patients with aplastic anemia PMID: 25032754
SPARC promoter methylation as an important factor in the tumorigenesis of gastric carcinomas. PMID: 25516351
SCD5 impairs SPARC and cathepsin B secretion in human melanoma cells and intracellular pH acidification. PMID: 25802234
High SPARC expression of the primary tumor is associated with a higher chance of achieving a pathological complete remission after TAC or TAC-NX chemotherapy. PMID: 25355716

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.